NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.26 -0.08 (-1.84 %)
(As of 05/22/2019 07:06 AM ET)
Previous Close$4.34
Today's Range$4.12 - $4.37
52-Week Range$2.36 - $10.54
Volume416,338 shs
Average Volume700,461 shs
Market Capitalization$223.88 million
P/E RatioN/A
Dividend YieldN/A
Beta3.25
Marinus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate exhibits anti-seizure, anti-depression, and anti-anxiety actions through its effects on synaptic and extrasynaptic GABAA receptors. It is also developing ganaxolone for cyclin-ependent kinase-like 5 deficiency disorder, PCDH19-related epilepsy, postpartum depression, refractory status epilepticus, and other indications. Marinus Pharmaceuticals, Inc. has a collaboration agreement with NovaMedica, LLC; and license and supply agreements with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was founded in 2003 and is based in Radnor, Pennsylvania.

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.10 per share

Profitability

Net Income$-36,730,000.00

Miscellaneous

Employees28
Market Cap$223.88 million
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) released its earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.03. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

7 analysts have issued 1-year target prices for Marinus Pharmaceuticals' shares. Their predictions range from $5.00 to $29.00. On average, they expect Marinus Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 287.3% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (5/14/2019)
  • 2. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (5/1/2019)
  • 3. LADENBURG THALM/SH SH analysts commented, "We don’t believe consensus includes much, if any, potential revenues in RSE. Given the spotlight on RSE from this open-label trial, we encourage investors to consider the near-term catalyst as its impact on Marinus’ revenue/earnings potential is possibly greater than its current epilepsy programs. The RSE luncheon included MD, its CFO, Ed Smith, its MD/PhD, who discussed the clinical and therapeutic aspects of RSE, the rationale for developing ganaxolone in RSE and the design of the ongoing Phase 2. Marinus’ VP, Corporate & Thomas J. “TJ” Lyons, presented findings from ongoing market assessment analyses." (5/1/2019)
  • 4. Mizuho analysts commented, "We highlighted our expectations for the phase 2 data in a previous note (available here). Magnolia is a multiple dose escalation study with ~60 patients randomized 1:1 with multiple dose cohorts and therefore not designed to hit statistical significance, in contrast to the phase 2 trial of Sage Therapeutics (SAGE, not rated) which was designed with a specific dose of brexanolone. In our view, the most important information to look for in the results will be a signal of efficacy along with information on a specific dose to be taken into Magnolia study." (9/25/2018)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

News headlines about MRNS stock have been trending somewhat negative this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Marinus Pharmaceuticals earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tanker (NAT), The Gabelli Dividend & Income Trust (GDV), Realty Income (O), Novavax (NVAX), Verastem (VSTM), TG Therapeutics (TGTX), Micron Technology (MU), XOMA (XOMA), Advanced Micro Devices (AMD) and Geron (GERN).

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (8.61%), BlackRock Inc. (6.08%), Goldman Sachs Group Inc. (3.46%), Geode Capital Management LLC (1.15%), Northern Trust Corp (1.02%) and Fosun International Ltd (0.74%). Company insiders that own Marinus Pharmaceuticals stock include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Oxford Asset Management LLP, Goldman Sachs Group Inc., Fosun International Ltd, Spark Investment Management LLC, Morgan Stanley, Jennison Associates LLC and JPMorgan Chase & Co.. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Northern Trust Corp, Jane Street Group LLC, Bailard Inc., Acadian Asset Management LLC, Charles Schwab Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $4.26.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $223.88 million. The biopharmaceutical company earns $-36,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com/.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 100, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  223 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel